Search in:

Advanced search

Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 3

Submit an article Journal homepage

123

Views

CrossRef citations to date

Altmetric

Review

Clinical trials with thiazolidinediones in subjects with Type 2 diabetes – is pioglitazone any different from rosiglitazone?

Sheila A Doggrell RMIT University, Pharmaceutical Sciences, School of Medical Sciences, PO Box 71, Victoria 3083, Australia +61 3 99257161; +61 3 99257063; [email protected]

, PhD DSc

Pages 405-420 | Published online: 28 Jan 2008

Cite this article
https://doi.org/10.1517/14656566.9.3.405

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007:356:2522-4
PubMed Web of Science ®Google Scholar
Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453-62
PubMed Web of Science ®Google Scholar
Laskso M. Benefits of strict glucose and blood pressure control in type 2 diabetes. Lessons from the UK Prospective Diabetes Study. Circulation 1999;99:461-2
PubMed Web of Science ®Google Scholar
Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43
PubMed Web of Science ®Google Scholar
Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34
PubMed Web of Science ®Google Scholar
Kannel WB, Anderson K, Wilson PW. White blood cell count and cardiovascular disease: insights from the Framingham Study. JAMA 1992;267:1253-6
PubMed Web of Science ®Google Scholar
Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-72
PubMed Web of Science ®Google Scholar
Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000;43:278-84
PubMed Web of Science ®Google Scholar
Nolan JJ, Jones NP, Patwardhan R, Deacon LF. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 2000;17:287-94
PubMed Web of Science ®Google Scholar
Ko SH, Song KH, Ahn YB, et al. The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes. Metabolism 2003;52:731-4
PubMed Web of Science ®Google Scholar
Sarafidis PA, Lasaridis AN, Nilsson PM, et al. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study. Metabolism 2005;54:1236-42
PubMed Web of Science ®Google Scholar
Derosa G, Cicero AF, D'Anagelo A, et al. Effects of 1 year with pioglitazone or rosiglitazone added to glimepiride on lipoprotein(a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther 2006;28:679-88
PubMed Web of Science ®Google Scholar
St Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005;25:553-9
PubMed Web of Science ®Google Scholar
Yu D, Murdoch SJ, Parikh SJ, et al. Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy. Diab Vasc Dis Res 2006;3:189-96
PubMedGoogle Scholar
Lautamäki R, Nuutila P, Airaksinen KE, et al. The effect of PPARγ-agonism on LDL subclass profile in patients with type 2 diabetes and coronary artery disease. Rev Diabet Stud 2006;3:31-8
PubMedGoogle Scholar
Chu CS, Lee KT, Lee MY, et al. Effects of rosiglitazone alone and in combination with atorvastatin on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 2006;97:646-50
PubMed Web of Science ®Google Scholar
Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes. Circulation 2002;106:679-84
PubMed Web of Science ®Google Scholar
Ghanim H, Dhindsa S, Aljada A, et al. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab 2006;91:3553-8
PubMed Web of Science ®Google Scholar
Pfützner A, Schöndorf T, Seidel D, et al. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabolism 2006;55:20-5
PubMed Web of Science ®Google Scholar
Hollander P, Yu D, Chou HS. Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes. Arch Intern Med 2007;167:1284-90
PubMedGoogle Scholar
Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8
PubMed Web of Science ®Google Scholar
Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:308-15
PubMed Web of Science ®Google Scholar
Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695-702
PubMed Web of Science ®Google Scholar
Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-32
PubMed Web of Science ®Google Scholar
King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. Diabetes Technol Ther 2002;4:145-51
PubMedGoogle Scholar
Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003;26:2493-9
PubMed Web of Science ®Google Scholar
Agarwal R. Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. Am J Physiol Renal Physiol 2006;290:F600-5
PubMed Web of Science ®Google Scholar
Forst T, Karagiannis E, Lübben G, et al. Pleiotropic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis 2007; [Epub ahead of print]
PubMed Web of Science ®Google Scholar
Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. A 6-month randomized placebo-controlled dose-study. Diabetes Care 2000;23:1605-11
PubMed Web of Science ®Google Scholar
Boyle PJ, King AB, Olansky L, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002;24:378-96
PubMed Web of Science ®Google Scholar
Van Wijk JP, De Koning EJ, Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003;23:1744-9
PubMed Web of Science ®Google Scholar
Olansky L, Marchetti A, Lau H. Multicenter retrospective assessment of thiazolidinediones monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipids levels. Clin Ther 2003;25(Suppl B):B64-80
Google Scholar
Peters Hamel AL, Kendall DM, Buse JB, et al. Impact of adjunctive thiazolidinediones therapy on blood lipids levels and glycemic control in patients with type 2 diabetes. Curr Med Res Opin 2004;20:215-23
PubMed Web of Science ®Google Scholar
Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104
PubMed Web of Science ®Google Scholar
Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002;25:708-11
PubMed Web of Science ®Google Scholar
Lacivita KA, Villarreal G. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Curr Med Res Opin 2002;18:363-70
PubMed Web of Science ®Google Scholar
Berhanu P, Kipnes MS, Khan MA, et al. Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidemia after treatment conversion from rosiglitazone while continuing stable statin therapy. Diab Vasc Dis Res 2006;31:39-44
Google Scholar
Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
PubMed Web of Science ®Google Scholar
Derosa G, D'Angelo A, Ragonesi PD, et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma levels in type 2 diabetic patients with the metabolic syndrome. J Clin Pharm Ther 2006;31:375-83
PubMed Web of Science ®Google Scholar
Derosa G, Cicero AF, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004;26:744-54
PubMed Web of Science ®Google Scholar
Deeg MA, Buse JB, Godberg RB. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007;30(10):2458-64
PubMed Web of Science ®Google Scholar
Chappuis B, Braun M, Stettler C, et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev 2007;23:392-9
PubMed Web of Science ®Google Scholar
Gerber P, Lübben G, Heusler S, Dodo A. Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus. Curr Med Res Opin 2003;19:532-9
PubMed Web of Science ®Google Scholar
Honisett SY, Stojanovska L, Sudhir K, et al. Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes. Diabetes Care 2003;11:3194
Google Scholar
Petrofsky J, Lee S, Cuneo M. Effects of aging and type 2 diabetes on resting and post occlusive hyperemia of the forearm; impact of rosiglitazone. BMC Endocr Disord 2005;24:4
Google Scholar
Pistrosch F, Passauer J, Fischer S, et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004;27:484-90
PubMed Web of Science ®Google Scholar
Natali A, Baldweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004;27:1349-57
PubMed Web of Science ®Google Scholar
Mertens FM, Visseren FL, De Koning EJ, Rabelink TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 2005;46:773-8
PubMed Web of Science ®Google Scholar
Sourij H, Zweiker R, Wascher TC. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care 2006;29:1039-45
PubMed Web of Science ®Google Scholar
Osman A, Otero J, Brizolara A, et al. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J 2004;147:e23
PubMed Web of Science ®Google Scholar
Choi D, Kim S-K, Choi S-H, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004;27:2654-60
PubMed Web of Science ®Google Scholar
Takagi T, Yamamuro A, Tamita K, et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003;146:E5
Web of Science ®Google Scholar
Nishio K, Sakurai M, Kusuyama T, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 2006;29:101-6
PubMed Web of Science ®Google Scholar
Hedblad B, Zambanini A, Nilsson P, Janzon L, Berglund G. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. J Intern Med 2007;261:293-305
PubMed Web of Science ®Google Scholar
Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin in patients with type 2 diabetes. Am Heart J 2007;153:445.e1-6
Web of Science ®Google Scholar
Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-6
PubMed Web of Science ®Google Scholar
Langenfield MR, Forst T, Hohnberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes: results for a controlled randomized study. Circulation 2005;111:2525-31
PubMed Web of Science ®Google Scholar
Pfützner A, Marx N, Lübben, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005;45:1925-31
PubMed Web of Science ®Google Scholar
Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-81
PubMed Web of Science ®Google Scholar
Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003;17:7-12
PubMed Web of Science ®Google Scholar
Sarafidis PA, Lasaridis AM, Nilsson PM, et al. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertens 2005;18:227-34
PubMed Web of Science ®Google Scholar
Bakris GL, Ruilope LM, Mcmorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006;24:2047-55
PubMed Web of Science ®Google Scholar
Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005;54:2206-11
PubMed Web of Science ®Google Scholar
Nakamura T, Ushiyama C, Osada S, et al. Pioglitazone reduces urinary podocyte in excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001;50:1193-6
PubMed Web of Science ®Google Scholar
St John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25:2058-64
PubMed Web of Science ®Google Scholar
Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II heart failure. J Am Coll Cardiol 2007;49:1696-704
PubMed Web of Science ®Google Scholar
Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther 2004;26:1400-10
PubMed Web of Science ®Google Scholar
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
PubMed Web of Science ®Google Scholar
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
PubMed Web of Science ®Google Scholar
Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure – a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941-8
PubMed Web of Science ®Google Scholar
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N Engl J Med 2007:357:28-38
PubMed Web of Science ®Google Scholar
Drazen JM, Morrissey S, Curfman GD. Rosiglitazone – continued uncertainty about safety. N Engl J Med 2007;357(1):63-4
PubMed Web of Science ®Google Scholar
Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95
PubMed Web of Science ®Google Scholar
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macrovascular Events): a randomised trial. Lancet 2005;366:1279-89
PubMed Web of Science ®Google Scholar
Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial in macroVascular Events 04). Stroke 2007;38:865-73
PubMed Web of Science ®Google Scholar
Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes with previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol 2007;49:1772-80
PubMed Web of Science ®Google Scholar
Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007;30(11):2773-8
PubMed Web of Science ®Google Scholar
Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH. Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;4:CD006060
Google Scholar
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus – a meta-analysis of randomized trials. JAMA 2007;298:1180-8
PubMed Web of Science ®Google Scholar
Derosa G, Cicero AF, Dangelo A, et al. Thiazolidinedione effects on blood pressure in diabetic patients with the metabolic syndrome treated with glimepiride. Hypertens Res 2005;28:917-24
PubMed Web of Science ®Google Scholar
Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract 2007;76:279-89
PubMed Web of Science ®Google Scholar
Aquilar D, Bozburt B, Pritchett A, Petersen NJ, Deswal A. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol 2007;50:32-6
PubMed Web of Science ®Google Scholar
Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007;262:157-72
PubMed Web of Science ®Google Scholar
Mattoo V, Eckland D, Widel M, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther 2005;27:554-67
PubMed Web of Science ®Google Scholar
Hanefeld M, Marx N, Pfützner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT study. J Am Coll Cardiol 2007;49:290-7
PubMed Web of Science ®Google Scholar
Chen LC, Ashcroft DM. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. J Clin Pharm Ther 2006;31:565-76
PubMed Web of Science ®Google Scholar
Matchaba P, Gitton X, Krammer G, et al. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials ÿ 1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clin Ther 2005;27:1196-24
PubMed Web of Science ®Google Scholar
Glaxo's statement on NEJM article. Available at: online.wsj.com/article/SB117976531260009684.html [accessed 14th June, 2007]
Google Scholar
Sarker A, Semple RK, Dinneen SF, O'Rahilly S, Martin SC. Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone. Diabetes Care 2004;27:2577-80
PubMed Web of Science ®Google Scholar
Gutschi LM, Malcolm JC, Favreau CM, Ooi TC. Parodoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy. Ann Pharmacother 2006;40:1672-6
PubMed Web of Science ®Google Scholar
Shargorodsky M, Wainstein J, Gavish D, et al. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens 2003;16:617-22
PubMed Web of Science ®Google Scholar
Paolisso G, Howard BV. Role of non-esterified fatty acids in the pathogenesis of type 2 diabetes mellitus. Diabet Med 1998;15:360-6
PubMed Web of Science ®Google Scholar
Gordon DJ, Probstfield DL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
PubMed Web of Science ®Google Scholar
Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994;121:641-7
PubMed Web of Science ®Google Scholar
Gimeno-Orna JA, Faure-Nogueras E, Sancho-Serrano MA. Usefulness of total cholesterol/HDL-cholesterol ratio in the management of diabetic dyslipidaemia. Diabet Med 2005;22:26-31
PubMedGoogle Scholar
Laakso M, Lehto S, Penttila L, Pyorala K. Lipids and lipoproteins predicting coronary artery mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993;88:1421-30
PubMed Web of Science ®Google Scholar
Anuurad E, Boffa MB, Koschinsky ML, Berglund L. Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin Lab Med 2006;26:751-72
PubMed Web of Science ®Google Scholar
Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam study. Circulation 1997;96:1432-7
PubMed Web of Science ®Google Scholar
Savage W, Estacio RO, Jeffers B, Schrier RW. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care 1996;19:1243-8
PubMed Web of Science ®Google Scholar
Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1999;1:165-72
PubMed Web of Science ®Google Scholar
Wolffenbuttel BH, Gomis R, Squartito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000;17:40-7
PubMed Web of Science ®Google Scholar
Vongerthavaravat V, Wajchenberg BL, Waitman JN, et al. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. Curr Med Res Opin 2002;18:456-61
PubMed Web of Science ®Google Scholar
Rosenstock J, Goldstein BJ, Vinik AI, et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (> 60 years): the rosiglitazone early vs sulphonylurea titration (RESULT) study. Diabetes Obes Metab 2006;8:49-57
PubMed Web of Science ®Google Scholar
Dailey GE, Noor MA, Park JS, Bruce S, Fiedorek FT. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med 2004;116:223-9
PubMed Web of Science ®Google Scholar
Orbay E, Sargin M, Sargin H, et al. Addition of rosiglitazone to glimepiride and metformin combination therapy in type 2 diabetes. Endocr J 2004;51:521-7
PubMed Web of Science ®Google Scholar
Khan M, Murray FT, Karunaratne M, Perez A. Pioglitazone and reductions in post-challenge glucose levels in patients with type 2 diabetes. Diabetes Obes Metab 2006;8:31-8
PubMed Web of Science ®Google Scholar
Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001;12:413-23
PubMed Web of Science ®Google Scholar
Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naïve patients with type 2 diabetes mellitus. Clin Ther 2003;25:1074-95
PubMed Web of Science ®Google Scholar
Scherbaum WA, Göke B. Metabolic efficacy and safety of once daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res 2002;34:589-95
PubMed Web of Science ®Google Scholar
Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The pioglitazone 027 study group. Clin Ther 2000;22:1395-409
PubMed Web of Science ®Google Scholar
Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10-7
PubMed Web of Science ®Google Scholar
Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-9
PubMed Web of Science ®Google Scholar
Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002;56:251-7
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Clinical trials with thiazolidinediones in subjects with Type 2 diabetes – is pioglitazone any different from rosiglitazone?

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Clinical trials with thiazolidinediones in subjects with Type 2 diabetes – is pioglitazone any different from rosiglitazone?

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date